SORAFENIB ZENTIVA 200mg tablets medication leaflet

L01EX02 sorafenib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors

Sorafenib is an antineoplastic medication used for the treatment of certain types of cancer, such as hepatocellular carcinoma, advanced renal cancer, and differentiated thyroid cancer. It works by inhibiting multiple kinases involved in tumor growth and angiogenesis.

The medication is taken orally, as directed by a doctor, usually twice daily. It is important for patients to adhere to the treatment regimen and undergo regular check-ups to monitor the response to therapy.

Patients should be aware of potential side effects, such as diarrhea, fatigue, or high blood pressure. It is important to inform the doctor of any unusual symptoms.

Common side effects include diarrhea, fatigue, high blood pressure, and skin rashes. In rare cases, severe reactions such as liver injury syndrome or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about SORAFENIB ZENTIVA 200mg

Substance: sorafenib

Date of last drug list: 01-06-2025

Commercial code: W66958001

Concentration: 200mg

Pharmaceutical form: tablets

Quantity: 112

Product type: generic

Price: 1802.64 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: REMEDICA LTD - CIPRU

Holder: ZENIVA K.S. - REPUBLICA CEHA

Number: 13430/2020/01

Shelf life: 2 years

Concentrations available for sorafenib

200mg, 400mg

Compensation lists for SORAFENIB ZENTIVA 200mg ZENTIVA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

1802.64 RON

1802.64 RON

0.00 RON